ISRCTN ISRCTN46864306
DOI https://doi.org/10.1186/ISRCTN46864306
Protocol serial number 01-2010
Sponsor Universidad Nacional de Colombia (Colombia)
Funder Universidad Nacional de Colombia (Colombia) - Research Division of Bogotá (DIB) (ref: 202010011419 Quipu Code)
Submission date
27/04/2010
Registration date
07/06/2010
Last edited
21/02/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Martha Losada-Camacho
Scientific

Crr 30 45-03 Edificio 450
Farmacia Oficina 215
Ciudad Universitaria
Bogotá
001
Colombia

Phone +57 (0)1 3114445288
Email mlosadac@unal.edu.co

Study information

Primary study designInterventional
Study designRandomised controlled pragmatic trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleImpact of pharmaceutical intervention in the treatment and quality of life of women with epilepsy: a randomised controlled pragmatic clinical trial
Study acronymIPHIWWE
Study objectivesWill the intervention of the pharmacist in the therapy of women with epilepsy to optimise treatment and improve their quality of life?
Ethics approval(s)Local medical ethics committee (Fundación Liga Central Contra la Epilepsia, sede Bogotá, LICCE, Acta 18/2009 Comité de Ética), 11/08/2009, ref: CEI-A1. Acta 18 de 2009
Health condition(s) or problem(s) studiedEpilepsy
InterventionThis is a two-armed pragmatic trial. The intervention group will receive usual medical care and are additionally given pharmaceutical care, health education and therapeutic drugs monitoring for six months. The control group continued with standard medical care.

All the patients continued drug treatment prescribed by the physician. Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of the study.
Intervention typeOther
Primary outcome measure(s)

Quality of Life in Epilepsy Inventory-31 (QOLIE-31). Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of treatment (six months).

Key secondary outcome measure(s)

Questionnaire measures will be administered to all participants at the beginning of baseline recording and at the end of treatment (six months):
1. Liverpool Adverse Events Profile
2. Spanish Center for Epidemiologic Studies, Depression Scale
3. Drug related problems

Completion date28/02/2011

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexFemale
Target sample size at registration182
Total final enrolment182
Key inclusion criteria1. Female, over 18 years
2. Diagnosis of epilepsy for more than a year
3. In treatment with antiepileptic drugs
4. Having at least one crisis in the last year
5. Ability to comply with the directions of the study
Key exclusion criteria1. Active major psychiatric disorder
2. Physical deficit (e.g., hemiplegia) or mental (e.g., mental retardation), preventing them from answering questionnaires
3. Drug/alcohol dependence
4. Involvement, earlier in the pharmaceutical care program of the institution
Date of first enrolment03/05/2010
Date of final enrolment28/02/2011

Locations

Countries of recruitment

  • Colombia

Study participating centre

Crr 30 45-03 Edificio 450
Bogotá
001
Colombia

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 31/10/2014 Yes No
Results article 15/02/2022 21/02/2022 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes

Editorial Notes

21/02/2022: Publication reference and total final enrolment added.